For patients with deep vein thrombosis (DVT), the presence of any component of metabolic syndrome (MetS) is independently associated with an increased risk for venous thromboembolism (VTE) recurrence, according to a study published online January in Blood Advances.

Lauren K. Stewart, M.D., and Jeffrey A. Kline, M.D., from the Indiana University School of Medicine in Indianapolis, conducted a retrospective analysis of a statewide database from 2004 to 2017 to measure the prevalence of MetS in patients with DVT and determine its effect on VTE recurrence. The frequency with which patients with DVT had a comorbid diagnosis of MetS components was assessed. Data were included for 151,054 patients with DVT.

The researchers found that VTE recurrence occurred in 17 percent of participants and increased stepwise for each criterion for MetS. The adjusted odds ratio for VTE was significant for all four components of MetS, with the largest for hyperlipidemia (odds ratio, 1.8). On Kaplan-Meier analysis for VTE recurrence, all four MetS variables were significant.

"These findings support the importance of recognizing MetS components in patients diagnosed with acute DVT and initiating appropriate therapies to reduce their effect on VTE recurrence risk," the authors write.

Indiana University received funding from Janssen and Pfizer pharmaceuticals for investigator-initiated research by one of the authors.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.